Dropping from a high of 47 requests for Regenerative Medicine Advanced Therapy (RMAT) designations in 2018, the FDA has received, so far, just 14 requests this year, according to new data from the FDA’s Center for Biologics Evaluation and Research (CBER).
Source: Drug Industry Daily